Cancer Research UK

Read about research news, funding opportunities and scientific events.

If you are unable to view this message correctly, click here

 
Cancer Research UK
Hero graphic for the weekly CRUK research update newsletter
 

Dear Voornaam

When we first reported on who applies for, and is awarded, our research funding in 2021, we committed to taking action to create a more inclusive and diverse research community. Two years on, were making progress. Overall success rates for men and women who apply for our funding are equal, were receiving increasing numbers of fellowship applications from people from ethnic minority backgrounds and were providing targeted support to encourage more Black students into cancer research.

While its good to see progress in the right direction, were not satisfied with the way things are. Now, as we report on our latest funding data, were also talking about the programmes weve introduced to support diversity at all stages of the research career pipeline. To drive change, our initiatives are removing barriers to participation at school and supporting the development of our leaders. And weve implemented positive action schemes to increase the equality of opportunity and experience at all career stages. Were proud to partner with some great organisations on these initiatives, and we hope youre inspired by the stories of the people weve worked with.

You can discover our latest data and read more about our work in our report.

Kind regards,
Iain Foulkes
Executive Director Research & Innovation
CEO Cancer Research Horizons
Cancer Research UK

 

Funding & Research Opportunities


 
29
Jul
 

Biomarker Project Awards

29 July 2023


 
29
Jul
 

Clinical Trial Award

29 July 2023


 
29
Jul
 

Experimental Medicine Award

29 July 2023


 
29
Jul
 

Prospective Sample Collection Awards

29 July 2023


 
06
Sep
 

Clinical Trial Fellowship Award

06 September 2023


 
07
Sep
 

Early Detection and Diagnosis Primer Award

07 September 2023


 
21
Sep
 

Early Detection and Diagnosis Programme Award

21 September 2023


 
21
Sep
 

Postdoctoral Research Bursary for Clinical Trainees

21 September 2023


year round image

Therapeutic Catalyst

 

Applications accepted all-year round


Year round image

Cancer Research Horizons Seed Fund

 

Applications accepted all-year round


 
 
Abena Amponsah black phd feature image link

MEET ABENA AMPONSAH, ONE OF OUR FIRST BLACK LEADERS IN CANCER PHD STUDENTS

Ahead of starting her PhD on our Black Leaders in Cancer Scholarship Programme in September, Abena Amponsah talked to us about her motivation for working in cancer research, what attracted her to our programme and her advice to those considering applying.


These programmes help cultivate a sense of belonging, which I believe will empower and inspire more Black students to aim higher and achieve their full potential, says Abena.


For her research project, Abena will explore how mechanical properties of the extracellular matrix influence immune cell response and cancer cell invasion to identify new targets for therapeutic interventions.

Read Abenas story
 
EDx conference inequalities session image link

JOIN US TO DISCUSS INEQUALITIES IN CANCER DETECTION AND DIAGNOSIS

At our global early detection conference this October, Kate Brain (Cardiff University) and Carmen Guerra (University of Pennsylvania) will chair a session on how to address the disparities between groups separated by ethnicity, gender, socioeconomic status and geography.


Take part in the session to discuss the reasons for and mechanisms of these differences, their impact on timeliness of detection and the interventions to reduce these inequalities.


Our three-day event, run in collaboration with the Canary Center at Stanford and OHSU Knight Cancer Institute, is packed with sessions to explore and debate opportunities in cancer early detection.

Register now
 
Horizons Twist Bioscience partnership image link
 

CANCER RESEARCH HORIZONS PARTNERS WITH TWIST BIOSCIENCE

Our innovation arm, Cancer Research Horizons, has partnered with Twist Bioscience, a biotechnology company that provides antibody discovery solutions based on their expertise in DNA synthesis.

The partnership grants Cancer Research Horizons access to Twists extensive phage display libraries for five years, which will greatly enhance its antibody discovery capabilities.

We look forward to using this technology to accelerate the delivery of high-quality therapeutics and diagnostics to cancer patients, said Hamish Ryder, CEO of Therapeutic Innovation at Cancer Research Horizons.

Read more
policy clinical survey image link
 

SHARE YOUR EXPERIENCE OF UK CLINICAL RESEARCH

Thank you to everyone whos already completed our survey on delivering and supporting clinical research in the UK. Your insights will help shape the policy calls on the UK clinical trial environment in our upcoming Manifesto for Cancer Research and Care.

The challenges affecting clinical research in the UK impact all disease areas, so were interested in hearing from a broad range of specialisms. Please consider sharing our survey with your colleagues and networks beyond oncology.

Complete the survey by 9 August
 
SMC calling for trustees image link

BECOME A TRUSTEE FOR THE SCIENCE MEDIA CENTRE

The Science Media Centre is calling for both emerging research leaders and researchers in senior strategic positions to join its board of trustees.


Trustees provide overarching governance, guidance on strategic direction and advice on how to respond to controversial, challenging or sensitive issues. And your work will contribute to the SMCs mission to disseminate accurate, reliable and evidence-based information about science through the media.


Applications are open until 4 September.

Find out more
 
DETERMINE Horizons blog image link

DETERMINE: A UNIQUE APPROACH TO RUNNING RARE CANCER TRIALS

There are far fewer treatments available for people with rare cancers but how do you address this unmet clinical need?

The DETERMINE trial offers a unique solution to this question. As the UKs first national precision medicine trial for rare cancers, DETERMINE allows patients to access off-label treatments in the context of a clinical trial, which not only streamlines access to potential treatments but also enables investigators to collect valuable data to benefit many more people with rare cancers in the future.

Cancer Research Horizons has played a crucial role in identifying and securing multi-pharma partnerships, bridging the gap between academia and industry to provide the targeted drugs used for evaluation across the trial.

The value of the trials cross-sector and collaborative approach has already been recognised through two awards.

Read more
 

UPCOMING RESEARCH EVENTS


 

14

Sep

 
 

14

Sep

 

Early Cancer Institute Annual Symposium

 

Cambridge, UK

14 September 2023


 

27

Sep

 
 

27

Sep

 

Webinar: How to harness the immune system to target cancer

 

Online

4:00 PM 27 September 2023


 

04

Oct

 
 

06

Oct

 

Molecular Analysis for Precision Oncology Congress

 

Paris, France

04 October 2023


 

10

Oct

 
 

12

Oct

 

The Early Detection of Cancer Conference

 

London, UK

10 October 2023


 

18

Oct

 
 

19

Oct

 

ELRIG UK Drug Discovery Conference

 

Liverpool, UK

18 October 2023


 

03

Nov

 
 

03

Nov

 

Workshop: Developing successful radiotherapy-drug combination projects with industry partners

 

Manchester, UK

03 November 2023


 

14

Nov

 
 

14

Nov

 

Children's and Young People's Cancer Research Conference

 

London, UK

14 November 2023


 

21

Nov

 
 

21

Nov

 

Cancer Research Horizons Innovation Summit

 

London, UK

21 November 2023


 

31

Jan

 
 

31

Jan

 

Tackling drug resistance in cancer: an interdisciplinary workshop

 

York, UK

31 January 2024


 

27

Feb

 
 

28

Feb

 

Data-driven Cancer Research Conference

 

Manchester, UK

27 February 2024


 
 
 

WHAT DID YOU THINK OF THIS EMAIL?

We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment.

 
THUMBS UP
 
THUMBS DOWN